DataMeds AI, Inc. (NASDAQ:MEDS) said its Corexa Health subsidiary is preparing for possible activity in the compounded peptide sector after the U.S. Food and Drug Administration proposed an interim policy covering compounding with certain peptides. The proposal is not yet final, and its timing, scope and list of eligible peptides remain subject to FDA action.
#FDA proposal follows advisory committee recommendation
The proposed measure, titled “Interim Access Policy for Compounding Using Certain Peptides,” was announced less than three months after the FDA’s Pharmacy Compounding Advisory Committee recommended easing restrictions on six peptides.
DataMeds AI said the policy could be changed, narrowed, suspended or withdrawn before taking effect. The company also identified uncertainty over which peptides may ultimately qualify for compounding and whether the policy will be finalised.
Precedence Research estimates that the U.S. compounding pharmacy market could increase from $18 billion in 2025 to over $34 billion annually by 2035. DataMeds AI cited that estimate while describing the potential market for compounded peptides.
#Corexa Pharmacy prepares for possible dispensing
Corexa Pharmacy, which operates as a 503A compounding pharmacy, intends to fill prescriptions for peptides that become eligible under the FDA policy if and when it takes effect. DataMeds AI said the pharmacy has begun evaluating potential suppliers of suitable drug substance and plans to formalise agreements with selected partners in the coming weeks.
Any future dispensing activity would remain subject to Section 503A of the Federal Food, Drug, and Cosmetic Act, applicable USP standards and the pharmacy laws and board requirements in each state where products are dispensed. The company also said supplier qualification and the timing, cost and terms of any agreements remain uncertain.
#Distribution plans span wholesale and logistics services
DataMeds AI said Corexa Distribution is licensed in all 50 states and intends to help independent pharmacies obtain compliant sources of peptide drug substance. Its 40,000 square foot warehouse in Lakeland, Florida, can support wholesale product sales to pharmacies and third-party logistics services for peptide manufacturers, according to the company.
The company said it plans to work with potential manufacturing partners and its network of 6,500+ independent pharmacies. It also identified demand, physician prescribing, cash-pay pricing, competition and product quality as factors that could affect the distribution operation.
#Technology division and Health Lives Here application
Corexa Tech & Hub is designed to receive prescriptions from physicians and direct them to Corexa Pharmacy or a local pharmacy selected by the patient. DataMeds AI said the division could see prescription volumes increase as physicians become a route through which consumers obtain peptides eligible for compounding. This is a forward-looking company statement rather than a reported result.
The company’s Electronic Benefits Verification service is intended to provide patients, providers and pharmacies with updates on changes in insurance coverage for peptides. DataMeds AI said it expects the peptide market to be predominantly cash pay initially, while noting that coverage, pricing and demand remain uncertain.
Health Lives Here is described as a mobile application that provides access to telemedicine, laboratory and pharmacy services. It also allows purchases of suitable medical foods and dietary supplements that complement prescribed medications.
#Initial focus on grey-market peptide users and GLP-1 patients
DataMeds AI said it initially plans to direct peptide marketing toward patients who have historically obtained peptides through the grey market. The company recently licensed technology from REBOOT, a subsidiary of Data Health Partners, for patients using FDA-approved GLP-1 receptor agonist drugs.
According to DataMeds AI, the patent-protected platform is intended to help those patients set, track and meet health and wellness goals. The company said its peptide-related marketing and services would remain subject to FDA, Federal Trade Commission and state requirements.
#Risks and conditions identified by the company
DataMeds AI said its plans depend on the FDA’s final decision, supplier qualification, compliance with pharmacy and distribution rules, physician prescribing and patient demand. Other risks identified by the company include competition from compounding pharmacies, outsourcing facilities, telehealth platforms and manufacturers of FDA-approved products.
The company also cited potential safety, adverse-event and product-quality issues involving compounded peptides, along with related product-liability, regulatory, enforcement and reputational risks. Additional uncertainties include insurance coverage, the performance of the Electronic Benefits Verification service, liquidity, capital resources and compliance with Nasdaq listing standards.
#Key Takeaways
- DataMeds AI said the FDA has proposed an interim policy for compounding using certain peptides, but the policy is not final.
- Corexa Pharmacy intends to fill prescriptions for eligible peptides if the policy takes effect and is reviewing potential suppliers.
- Corexa Distribution is licensed in all 50 states and operates a 40,000 square foot warehouse in Lakeland, Florida.
- The company said its technology division will route prescriptions through Health Lives Here and provide insurance-coverage updates through Electronic Benefits Verification.
- DataMeds AI identified regulatory, supplier, safety, demand, competition, insurance, liquidity and Nasdaq compliance risks affecting its plans.
Original source: Read original article